Targeting CD47 as a Novel Immunotherapy for Breast Cancer
FRONTIERS IN ONCOLOGY(2022)
摘要
Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor-targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety and efficacy in breast cancer. In this review, we summarized different therapeutic mechanisms targeting CD47 and its prognostic role and therapeutic value in breast cancer.
更多查看译文
关键词
CD47, SIRP alpha, breast cancer, immunotherapy, immune checkpoint inhibitors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要